IM Cannabis Corp. (IMCC) Q3 2024 Earnings Call Transcript Summary
IM Cannabis Corp. (IMCC) Q3 2024 Earnings Call Transcript Summary
The gross profit for Q3 2024 increased to $3.1 million, up 19% over Q3 2023.The following is a summary of the IM Cannabis Corp. (IMCC) Q3 2024 Earnings Call Transcript:
以下是Im 大麻股 (IMCC) 2024年第三季度 業績會會議記錄的摘要：
Financial Performance:
財務表現:
IM Cannabis reported a revenue increase of 12.2% in Q3 2024 compared to Q3 2023, mainly driven by a 278% increase in German revenue.
Operating expenses decreased by 16% compared to Q3 2023, resulting in an operating expenses ratio of 30% in Q3 2024 versus 40% in Q3 2023.
The gross profit for Q3 2024 increased to $3.1 million, up 19% over Q3 2023.
Im 大麻股在2024年第三季度的營業收入與2023年第三季度相比增加了12.2%，主要是由於德國營業收入增加了278%。
與2023年第三季度相比，營業費用減少了16%，導致2024年第三季度的營業費用比率爲30%，而2023年第三季度爲40%。
2024年第三季度的毛利潤增加至310萬美金，比2023年第三季度增加了19%。
Business Progress:
業務進展：
Focus on building a solid foundation for accelerated growth in Germany in 2025 with full integration of German and Israeli teams for efficient resource usage.
Introduction of three Israeli-grown cannabis strains in Germany representing successful supply chain integration.
專注於爲2025年在德國加速增長建立堅實基礎，全面整合德國和以色列團隊，以實現資源的有效使用。
在德國推出三種以色列種植的大麻品種，代表着成功的供應鏈整合。
Opportunities:
機會：
Market expansion: Growth driven by partial legalization in Germany and increasing number of patients using cannabis-based treatments.
Product Innovation: Launch of three new cannabis strains in Germany represents product innovation aligned with market needs.
Operational Efficiency: Enhanced operating efficiency through team integration and resource optimization.
市場擴展：德國部分合法化推動的增長，以及使用大麻股治療的患者數量增加。
產品創新：在德國推出三種新的大麻股品種，代表了與市場需求一致的產品創新。
運營效率：通過團隊整合和資源優化提升營業效率。
Risks:
風險：
External factors like the ongoing war impacting Israeli operations, leading to supply chain delays and affecting medical cannabis license renewals.
外部因素，如持續的戰爭影響以色列的運營，導致供應鏈延遲，並影響醫療大麻股許可證的續期。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
